Literature DB >> 7531514

Somatic mutations of the PIG-A gene found in Japanese patients with paroxysmal nocturnal hemoglobinuria.

N Yamada1, T Miyata, K Maeda, T Kitani, J Takeda, T Kinoshita.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematologic disorder caused by deficient biosynthesis of the glycosylphosphatidylinositol (GPI) anchor. PIG-A, an X-linked gene that participates in the first step of GPI-anchor synthesis, is responsible for PNH. Abnormalities of the PIG-A gene have been demonstrated in all patients with PNH that have been studied to date. In this study, we analyzed 14 Japanese patients with PNH and identified 15 somatic mutations of PIG-A. The mutations included eight single-base changes and seven frame shift mutations. The single-base changes were two nonsense, three missense, and three splice site mutations. The frame shift mutations were four single-base deletions, two single-base insertions, and a replacement of two bases with one. They were all different, except for the same missense mutation being found in two patients. Moreover, these mutations were distributed in various regions of the gene. These results indicated that the mutations occurred at random sites and that there is no mutation hot spot in the PIG-A gene. All the mutations resulted in complete loss of function. Interestingly, the granulocytes in these patients contained variable proportions of mutant cells, suggesting that clonal expansion is not determined solely by mutations but is influenced by another factor(s).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531514

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.

Authors:  Yuzuru Kanakura; Kazuma Ohyashiki; Tsutomu Shichishima; Shinichiro Okamoto; Kiyoshi Ando; Haruhiko Ninomiya; Tatsuya Kawaguchi; Shinji Nakao; Hideki Nakakuma; Jun-ichi Nishimura; Taroh Kinoshita; Camille L Bedrosian; Marye Ellen Valentine; Gus Khursigara; Keiya Ozawa; Mitsuhiro Omine
Journal:  Int J Hematol       Date:  2011-01-12       Impact factor: 2.490

2.  Mutation analysis of the PIG-A gene in Korean patients with paroxysmal nocturnal haemoglobinuria.

Authors:  J H Yoon; H I Cho; S S Park; Y H Chang; B K Kim
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

3.  Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.

Authors:  V C Taylor; M Sims; S Brett; M C Field
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

Review 4.  Paroxysmal nocturnal haemoglobinuria: nature's gene therapy?

Authors:  R J Johnson; P Hillmen
Journal:  Mol Pathol       Date:  2002-06

Review 5.  Relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Authors:  Taroh Kinoshita; Norimitsu Inoue
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

Review 6.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

7.  The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Authors:  David J Araten; Lucio Luzzatto
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

8.  Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.

Authors:  Yuzuru Kanakura; Kazuma Ohyashiki; Tsutomu Shichishima; Shinichiro Okamoto; Kiyoshi Ando; Haruhiko Ninomiya; Tatsuya Kawaguchi; Shinji Nakao; Hideki Nakakuma; Jun-ichi Nishimura; Taroh Kinoshita; Camille L Bedrosian; Keiya Ozawa; Mitsuhiro Omine
Journal:  Int J Hematol       Date:  2013-08-11       Impact factor: 2.490

9.  AOHE: manuscript AOHE-D-16-00564 paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy-with large granular lymphocytic leukemia.

Authors:  Nathan Visweshwar; Michael Jaglal; Cassie Booth; Patrick Griffin; Damian Laber
Journal:  Ann Hematol       Date:  2016-07-23       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.